Article

newsobserver.com on 2016-12-29 16:28

Cempra shares plummet after drug fails to win approval

The federal agency did not outright reject the oral and intravenous formulas of the experimental antibiotic Solithera, which is aimed at treating ...

Related news

Cempra seeks FDA approval for flu drug courier-tribune.com
Chapel Hill , Raleigh
Chapel Hill's Cempra shares plummet Friday morning following drug results bizjournals.com
Chapel Hill
MOcular Therapeutix shares plummet after FDA pushes back on eye-drug approval marketwatch.com
Pozen reports no progress on drug approval; shares drop bizjournals.com
Chapel Hill
MUPDATE: AbbVie shares plummet 11.7% on cancer drug results marketwatch.com
BAcadia Shares Plummet After FDA Finds Flaws in Drug Application barrons.com
Cempra CEO’s retirement raises red flag newsobserver.com
Research Triangle Park , Chapel Hill , Wall Street
MAdamas Pharma shares soar on Parkinson's dyskinesia drug approval marketwatch.com
MVertex shares up more than 1% after FDA drug approval marketwatch.com
Vertex drug gets FDA approval Boston Herald
Wall Street , Somerville
Chapel Hill drug developer Cempra expands trial bizjournals.com
Chapel Hill
Drugmaker shares plummet ahead of FDA meeting on antibiotic The Findlay Courier
Wall Street
MZogenix's shares rise on FDA approval of seizure drug marketwatch.com
Chapel Hill’s Cempra awaits FDA ruling on pneumonia drug newsobserver.com
HU.S. Approval of Biogen Alzheimer’s Drug Sends Shares Soaring hamodia.com
Wall Street , Japan
MAlnylam shares drop 1.8% on new FDA approval strategy for rare disease drug marketwatch.com
MEpizyme's shares fall after receiving new FDA approval for cancer drug marketwatch.com
MMedicines Co. shares surge 2.5% on FDA approval of drug for complicated UTIs marketwatch.com
MAmicus shares drop 28% after FDA denies quick drug approval marketwatch.com
Cempra shares pop following pneumonia treatment's trial results bizjournals.com
Chapel Hill